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A B S T R A C T 
Growth impairment in cystic fibrosis (CF) is 
worsened by liver disease. Children with CF 
have serum levels of insulin-like growth factor-I 
(IGF-I) that are lower than expected for their 
normal growth hormone (GH) production. In 
children with CF-related liver disease (CFLD), 
response to endogenous GH is further reduced. 
We present our experience with two young 
children with CFLD given recombinant human 
GH (rhGH). The first patient was a 5 year-old 
female with CFLD and poor growth who 
responded well for VA years to rhGH therapy 
during her initial course and without a signifi-
cant increase in serum IGF-I, but with a sub-
stantial increase in IGF-I concentration when 
the GH dose was increased. The second patient 
was a 5 month-old male with advanced liver 
disease who had transient improved growth and 
liver function following rhGH. These patients 
suggest that rhGH is safe and may be effective 
in children with CFLD. 
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I N T R O D U C T I O N 
In 1938, the mean life expectancy for children 
with cystic fibrosis (CF) was less than one year, 
improving to 16 years by the mid-1970s and 
currently to 36.5 years1,2. Resulting from a mutation 
in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, CF has an incidence of one 
in 3,500 live births2. Some manifestations of this 
disease are due to defective CFTR chloride channel 
function and others are the result of cellular 
responses to mutant CFTR3"5. The interplay of these 
effects, with poor nutrient absorption and increased 
metabolic demand of illness, is thought to account 
for poor growth, although direct effects on growing 
bone and muscle cannot be discounted. Childhood 
height and weight for age are independent pre-
dictors of lung function and survival6,7. 
Children with CF have normal growth hormone 
(GH) secretion, but low serum insulin-like growth 
factor-I (IGF-I) concentrations8. With CF-related 
liver disease (CFLD) IGF-I levels may be further 
reduced9. GH stimulation of hepatic production of 
IGF-I is the main source of circulating IGF-I. GH 
also stimulates hepatic production of the principal 
binding protein of circulating IGF-I, IGF binding 
protein-3 (IGFBP-3) and the acid labile subunit 
(ALS). Some 90% of IGF-I circulates as a ternary 
complex with IGFBP-3 and ALS, the latter stabili-
zing the complex10. Administration of recombinant 
human GH (rhGH) may improve growth by 
stimulating IGF-I synthesis in the liver (endocrine) 
and bone (paracrine), as well as directly stimulating 
pre-chondrocyte differentiation. Studies suggest 
that rhGH treatment improves the growth and 
clinical course in patients with CF11'12. More speci-
fically, rhGH administration has been associated 
with increased lean body mass, improved lung 
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function, and decreased hospitalizations. 
We have treated two children with low IGF-I 
production and impaired growth, despite substantial 
caloric intake. Adequacy of endogenous GH 
production was determined in both children. We 
hypothesized that the addition of exogenous rhGH 
would stimulate target tissues to improve IGF-I 
production. 
PATIENT REPORTS 
Patient 1 
This child had mild lung disease with infrequent 
respiratory symptoms, despite being homozygous 
for the AF508 mutation. She was too young for 
reliable pulmonary function testing. She had 
hepatomegaly and markedly elevated serum trans-
aminase levels at 4 months of age. Diagnosed with 
chronic liver disease, she had been stable on 
medical therapy for >2 years. 
At 5 years of age, standard deviation score 
(SDS) for height was -4 and for weight -3.9, with 
poor growth velocity (GV), of 3.5 cm/yr (-4 SDS). 
Her pre-albumin level was low (12 mg/dl [normal 
{nl}: 20-40]) despite gastrostomy tube and oral 
intake, which was greater than calculated energy 
needs of 135 kcal/kg/day. Thyroid, adrenal function 
and blood glucose levels were normal. After a GH 
stimulation test using glucagon and Clonidine 
resulted in a peak response of 9.9 ng/ml, we 
initiated treatment with rhGH (0.3 mg/kg/wk). Her 
intake improved slightly, from 171 to 194 kcal/ 
kg/day. She had suboptimal weight gain in the 12 
months before (2.8 g/d) and after (3.1 g/d, nl for 
age 5-8 g/d) starting rhGH. Nonetheless, GV 
increased to 8.4 cm/yr over the first 6 months of 
rhGH treatment, but serum IGF-I and IGFBP-3 
concentrations were unaffected (from 54 to 66 
ng/ml for IGF-I [nl for age 57-260] and from 1.4 to 
2.1 mg/1 for IGFBP-3 [nl for age 1.1 to 5.2]). At 9 
months into her therapy, her GV continued at 7.5 
cm/yr, but by 12 months her growth slowed to 4 
cm/year. We increased her rhGH dose to 0.35 
mg/kg/wk. Her IGF-I level was obtained one month 
later and had increased to 183 ng/ml, and her AST 
and ALT normalized (from pretreatment 49 and 45 
U/l to 35 and 39 U/l). In addition, her growth rate 
improved over the next 7 months to 6.4 cm/yr. 
Patient 2 
This 5 month-old male infant with CFLD and 
poor growth was born full term with a meconium 
cyst that was removed along with 15 cm of bowel 
in the neonatal period. CFTR genotyping revealed 
combined heterozygosity for the AF508 mutation 
and a nonsense allele (Q493X). 
Total parenteral nutrition (TPN) was provided 
because of prolonged feeding difficulties, with 
inability to tolerate more than 200 ml/day through 
the gastrostomy tube without profuse diarrhea. He 
subsequently developed severe liver dysfunction, 
attributed to TPN and CF. Other complications 
included coagulopathy, ascites, esophageal varices, 
and gastric erosions. He was listed for liver trans-
plantation; however, weight gain and linear growth 
were desired to improve outcome with transplanta-
tion. 
Growth and weight gain were inadequate; length 
was 62.5 cm and weight was 6.04 kg, -1.3 SDS for 
length and -1.8 SDS for weight. His birth length 
was 48.3 cm (-0.65 SDS) and weight 2.75 kg (-1.3 
SDS). At 5 months of age, his weight for height 
was calculated at the 10th percentile. He had 
jaundice and hepatomegaly. Laboratory studies 
were remarkable for a total bilirubin of 24.3 mg/dl, 
with a conjugated fraction of 22.1. His serum AST 
and ALT. concentrations were 508 and 341 U/l, 
respectively. PT and PTT were mildly elevated and 
the pre-albumin level in serum was low. Endocrine 
evaluation revealed normal thyroid function and 
GH production; peak random GH level was 18.4 
ng/mlr Although serum IGF-I was undetectable, 
IGFBP-3 and ALS levels were normal (0.7 mg/1 [nl 
for age 0.7-3.6] and 1.5 mg/1 [nl for age 0.7-5.6], 
respectively), indicating some hepatic response to 
endogenous GH. 
Treatment with rhGH was begun in an effort to 
improve growth and weight, and accelerate the 
transition to enteral feeds. His growth immediately 
improved. Within one month, his length was -0.6 
SDS and his weight was -1.3 SDS. There was an 
improvement in muscle mass and tone and in 
overall physical activity. In addition, he was 
transitioned to full enteral feeds within six weeks. 
No other changes to his care were introduced. His 
serum transaminase concentrations improved, and 
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total and conjugated bilirubin levels decreased to 
12.8 and 11.2, respectively. Coagulation studies 
and pre-albumin concentrations normalized. IGF-I 
reached detectable levels. Plans for liver trans-
plantation were postponed. 
Improvement did not persist, however. Approxi-
mately two months into therapy, weight gain and 
linear growth rates declined, liver function deterior-
ated, and he developed persistent coagulopathy. His 
weight dropped to that before treatment and growth 
rate decreased below normal for his age. Serum 
IGF-I concentration also fell below the normal 
range. Successful transition to enteral feeds was 
one of the decisive factors to pursue liver trans-
plantation. At 10 months of age, he received his 
liver transplant and is doing well. 
DISCUSSION 
The use of rhGH for growth promotion in 
individuals with CF is increasing. There is, how-
ever, no safety and efficacy experience with rhGH 
treatment in patients with CFLD. Impaired liver 
function could result in impaired IGF-I production 
despite normal GH secretion. GH has both direct 
effects on growing bone differentiation and indirect 
growth effects through IGF-I produced by the liver 
or other tissues. One mechanism for the positive 
responses to GH seen in children with CF may be 
increased direct effects of GH and increased local 
production of IGF-I in growing tissues. 
Our first patient had an initial dramatic im-
provement in GV without an increase in circulating 
IGF-I concentrations, implying a local effect of 
pharmacological levels of GH in growing bone. 
Local GH effects are differentiation and prolifera-
tion of chondrocytes with stimulation of paracrine 
IGF-I synthesis. CFTR expression in osteoblasts 
indicates a possible mechanism for CF-related 
growth failure13. Extremely low serum IGF-I 
concentration is seen with normal or near-normal 
growth in hepatic IGF-I or ALS knockout mice and 
ALS gene mutation in humans, indicating that the 
direct effects of GH in growing tissues and local 
(paracrine) production of IGF-I may be sufficient 
for normal growth14"17. 
We concluded that the low serum IGF-I con-
centration in patient 1 was the result of CFLD 
and not directly related to the growth problem. 
Therefore, IGF-I may not be a good marker for 
determining candidates for rhGH therapy or for the 
efficacy of rhGH therapy in CFLD. Subsequently, 
the increase in circulating IGF-I concentration 
following the increased dosage also coincided with 
normalization of the liver transaminase level in 
serum. It is not possible to distinguish whether this 
improvement was secondary to the increased dose 
or improved liver function. In either case, the 
improved liver function and IGF-I production were, 
paradoxically, associated with a decline in GV. 
Effects of GH on the liver are unclear. Neonatal 
hepatitis secondary to cholestasis occurs with con-
genital GH deficiency18 μ '. Animal models suggest 
an integral role for GH in liver regeneration. 
Pennisi et al.20 performed partial (70%) hepatec-
tomies in three groups of mice: a) GH antagonist 
transgenic mice, in which the action of GH is 
blocked, b) liver IGF-I deficient mice that also 
lacked ALS, and c) control animals with normal 
GH and IGF-I levels. GH antagonist mice demon-
strated the worst survival rate immediately follow-
ing surgery (57%) compared to the IGF-I and ALS 
deficient mice (88%) and controls (100%). Follow-
ing partial hepatectomy, control mice were able to 
fully regenerate their liver mass by four days. IGF-I 
and ALS deficient mice were able to fully 
regenerate their liver to the original mass by seven 
days. The GH antagonist mice that survived were 
only able to regenerate to 70% of their original liver 
mass by four days, and did not regenerate further 
before sacrifice at seven days. Desbois-Mouthon et 
al. further describe the complex paracrine inter-
action of IGF-1 at the rodent liver. Their group 
utilized a liver IGF-I receptor inactivation mouse to 
demonstrate a need for upregulation (from the 
minimal baseline state) of the IGF-I receptor during 
liver regeneration21. 
The second patient had a relatively uncommon 
indication for rhGH treatment in children. GH is 
indicated for treatment of short gut syndrome in 
adults, although the data on effectiveness are 
conflicting22 2 '. There may be a faster transition 
from TPN to enteral feeds, improving quality of life 
and reducing health care costs24·2"1. Shulman et al. 
reported an increase in the mucosal height 
following GH therapy in rats that had previously 
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undergone 75% resection of the ileum26. Regenera-
tion of rat gut mucosa has been improved with the 
addition of glutamine to GH therapy27. Although 
the short gut syndrome indication for rhGH is not 
exclusive to adults, experience in children is 
limited28·29. 
The infant patient suffered from the various 
effects of CF with end-stage liver disease, short gut 
syndrome, and severe growth failure. He had an 
initial therapeutic response to rhGH, including an 
increase in weight gain and linear growth, with a 
successful transition to enteral feedings, and an 
increase in circulating IGF-I concentration. These 
findings suggest that early in the course of CFLD, 
rhGH may be useful. As liver disease progresses 
and chronic catabolism ensues, however, the ability 
of the liver and other target tissues to mount an 
IGF-I response to GH may be lost. 
Researchers have examined GH therapy for 
other catabolic states, primarily in the adult popula-
tion. The most extensively studied indication for 
rhGH in adult catabolism is for HIV-associated 
wasting. In 2004, Moyle et al. reported improve-
ments in lean body mass, physical performance and 
quality of life in a large (757 patients) randomized, 
double-blind, placebo-controlled trial of rhGH in 
HIV30. Other studies have tried to reverse the 
catabolic state and overcome resistance to GH. 
Wallace et al. observed improvements in serum 
levels of IGF-I, IGFBP-3 and ALS in a randomized, 
double-blind, placebo-controlled, cross-over study 
of GH therapy in nine adults with chronic liver 
disease31. In addition, there was an improvement in 
lean tissue mass of approximately 10% (measured 
by total body potassium and bioelectrical impe-
dance). Worsening ascites and edema were noted, 
however, in four of the individuals. Neither of our 
patients demonstrated worsening of ascites or 
edema during rhGH therapy. Nonetheless, this 
complication should be considered when treating 
children with hypoproteinemia or ascites. 
Both patients illustrate that rhGH therapy may 
be used in children with CFLD. No adverse events 
were associated with rhGH therapy. Both children 
demonstrated a noticeable increase in growth 
despite their liver disease. Variable biochemical 
responses were noted following GH augmentation, 
suggesting more important direct GH effects on 
growing tissue and in stimulating paracrine IGF-I 
production. These findings suggest the need for 
additional studies into the biochemical effects of 
GH treatment on individuals with CF, as well as in 
individuals with liver disease. 
REFERENCES 
1. Orenstein D M , Winn ie GB, Al tman H. Cystic f ibrosis; a 
2 0 0 2 update . J P e d i a t r 2 0 0 2 ; 140: 156-164. 
2. Foundat ion CF. Pat ient Regis t ry 2 0 0 5 Annual Report . 
Bethesda , M D , 2006 . 
3. Vire l la-Lowel l I, Her l ihy JD, Liu B, L o p e z C, Cruz P, 
Mul le r C, Baker H V , Flotte TR. Ef fec t s of C F T R , 
interleukin-10, and Pseudomonas aeruginosa on gene 
express ion prof i les in a C F bronchia! epithelial cell 
Line. Mol Ther 2 0 0 4 ; 10: 562 -573 . 
4. Sagel SD, Accurso FJ. Mon i to r ing in f lammat ion in CF. 
Cytokines . Clin Rev Al le rgy Immuno l 2002 ; 23: 41-57. 
5. Stalvey MS, Mul le r C, Scha tz DA, Wasserfa l l CH, 
C a m p b e l l - T h o m p s o n M L , The r i aque D W , Flotte TR, 
Atkinson MA. Cyst ic f ibrosis t r ansmembrane conduc-
tance regulator de f ic iency exacerba tes islet cell dys-
func t ion af ter beta-cel l injury. Diabe tes 2 0 0 6 ; 55: 1939-
1945. 
6. Kons tan M W , But ler S M , W o h l M E , S toddard M, 
Matousek R, W a g e n e r JS, Johnson C A , Morgan WJ ; 
Invest igators and Coord ina to r s of the Epidemiologic 
Study o f Cyst ic Fibrosis . Growth and nutrit ional 
indexes in early life predict pu lmonary funct ion in 
cystic f ibrosis . J P e d i a t r 2 0 0 3 ; 142: 624 -630 . 
7. Beker LT, Russek -Cohen E, Fink RJ. Stature as a 
prognos t ic fac tor in cyst ic f ibros is survival . J A m Diet 
Assoc 2001 ; 1 0 1 : 4 3 8 - 4 4 2 . 
8. Laursen EM, Lanng S, Rasmussen M H , Koch C, 
Skakkebaek N E , Mul le r J. N o r m a l spontaneous and 
st imulated G H levels despi te decreased IGF-I concen-
trat ions in cyst ic f ibros is pat ients . Eur J Endocr inol 
L999; 140: 315-321 . 
9. Wu YL, Ye J, Z h a n g S, Z h o n g J, Xi RP. Clinical signi-
f icance of serum IGF-I , IGF-I I and IGFBP-3 in liver 
cirrhosis . Wor ld J Gas t roen te ro l 2004 ; 10: 2740-2743 . 
10. Rosenb loom AL. Phys io logy and d isorders of the 
growth ho rmone recep to r ( G H R ) and G H - G H R signal 
t ransduct ion. Endocr ine 2 0 0 0 ; 12: 107-119. 
11. Hardin DS, Ferkol T , Ahn C, Dre imane D, Dyson M, 
Morse M, Pres t idge C , Rice J, Se i lhe imer DK. A retro-
spect ive study of g rowth ho rmone use in adolescents 
with cystic f ibrosis . Clin Endocr inol ( O x f ) 2005 ; 62: 
560-566 . 
12. Hardin DS. A d a m s - H u e t B. Brown D, Chatf ie ld B, 
Dyson M, Ferkol T, Howens t ine M, Pres t idge C, Royce 
F, Rice J, Se i lhe imer DK, S tee lman J, Shepherds R. 
Growth ho rmone t rea tment improves growth and 
clinical status in prepuber ta l chi ldren with cystic 
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM 
GH IN CYSTIC FIBROSIS LIVER DISEASE 7 9 7 
f ibrosis : resul ts of a mul t icenter randomized cont ro l led 
trial. J Clin Endocr ino l M e t a b 2 0 0 6 ; 91: 4 9 2 5 - 4 9 2 9 . 
13. Shead EF, Hawor th C S , Cond l i f f e A M , M c K e o n DJ, 
Scott M A , C o m p s t o n JE. Cyst ic f ibrosis t r a n s m e m b r a n e 
conduc tance regula tor ( C F T R ) is expressed in h u m a n 
bone. T h o r a x 2 0 0 7 ; 62: 6 5 0 - 6 5 1 . 
14. D o m e n e H M , Bengo lea SV, Jasper HG, Boisc la i r YR. 
Acid- labi le subuni t def ic iency: phenotyp ic similari t ies 
and d i f f e rences be tween human and mouse . J Endo-
crinol Invest . 2005 ; 2 8 (Suppl) : 43-46 . 
15. H w a V, Haeus l e r G, Pratt KL, Little B M , Frisch Η, 
Koller D, Rosenfe ld RG. Total absence of func t iona l 
acid labile subuni t , resul t ing in severe insulin-l ike 
growth fac tor de f ic iency and modera te growth fa i lure . 
J Cl in Endocr ino l M e t a b 2 0 0 6 ; 9 1 : 1 8 2 6 - 1 8 3 1 . 
16. D o m e n e H M , Bengo lea SV, Mar t inez AS, Rope la to 
M G , Pennis i P, Scagl ia P, Heinrich JJ, Jasper HG. 
Def ic iency o f the c i rcula t ing insulin-like growth fac tor 
sys tem associa ted with inactivation of the acid- labi le 
subuni t gene . Ν Engl J Med 2004 ; 350: 570-577 . 
17. D o m e n e H M , Mar t inez AS , Frystyk J, Bengo lea SV, 
Rope la to M G , Scagl ia PA, Chen J W , Heuck C, 
Wol the r s O D , Heinr ich JJ, Jasper HG. Norma l growth 
spurt and final height despi te low levels of all f o r m s o f 
c i rcula t ing insulin-l ike growth factor-I in a pat ient with 
acid- labi le subuni t def ic iency . Horm Res 2 0 0 7 ; 67: 
243 -249 . 
18. Spray C H , M c K i e r n a n P, Wa ld ron K.E, Shaw N, Kirk J, 
Kelly DA. Invest igat ion and ou tcome of neonata l 
hepati t is in infants with hypopi tu i tar ism. Acta Paedia t r 
2000 ; 89: 951 -954 . 
19. C h o o - K a n g LR, Sun C C , Coun t s DR. Choles tas i s and 
hypog lycemia : mani fes ta t ions o f congenital an ter ior 
hypopi tu i ta r i sm. J Cl in Endocr inol M e t a b 1996; 81: 
2786 -2789 . 
20. Pennisi PA, K o p c h i c k JJ, Thorge i r sson S, LeRoi th D, 
Yakar S. Role o f g rowth hormone ( G H ) in liver 
regenera t ion . Endocr ino logy 2004 ; 145: 4 7 4 8 - 4 7 5 5 . 
21. Desbo i s -Mou thon C, W e n d u m D, Cadore t A, Rey C, 
Leneuve P, Blaise A, Housse t C, T ronche F, Le Bouc 
Y, Ho lzenbe rge r M. Hepa tocy te prol i ferat ion dur ing 
liver regenera t ion is impaired in mice with liver-
speci f ic 1GF-1R knockout . F A S E B J 2006 ; 20: 773-
775. 
22. Scolap io JS, Camil ler i M, F leming CR, O e n n i n g LV, 
Burton DD, Sebo TJ, Batts KP, Kelly DG. Ef fec t of 
growth ho rmone , g lu tamine , and diet on adapta t ion in 
shor t -bowel syndrome: a r andomized , cont ro l led s tudy. 
Gas t roen te ro logy 1997; 113: 1074-1081. 
23 . Szkudla rek J, J eppesen PB, Mor tensen PB. E f f ec t o f 
high dose growth h o r m o n e with g lu tamine and no 
change in diet on intestinal absorp t ion in short bowel 
patients: a r andomised , doub le bl ind, c rossover , p l acebo 
control led s tudy. G u t 2 0 0 0 ; 47: 199-205. 
24 . Byrne T A , W i l m o r e D W , Iyer K, Dibaise J, C l ancy K, 
Robinson M K , C h a n g P, Ger tne r J M , Lautz D. G r o w t h 
hormone , g lu tamine , and an opt imal diet r educes paren-
teral nutri t ion in pa t ien ts with short bowel syndrome: a 
prospect ive , r a n d o m i z e d , p lacebo-cont ro l led , doub le -
blind clinical trial. Ann Surg 2 0 0 5 ; 242 : 6 5 5 - 6 6 1 . 
25 . Mig l i acc io -Wal le K, C a r o JJ, Mol le r J. E c o n o m i c 
impl icat ions o f g rowth h o r m o n e use in pat ients with 
short bowel syndrome . Cur r Med Res Opin 2 0 0 6 ; 22 : 
2055 -2063 . 
26. Shulman DI, Hu CS , Ducket t G , Lava l lee -Grey M. 
Ef fec t s of shor t - term growth h o r m o n e therapy in rats 
unde rgo ing 7 5 % small intestinal resect ion. J Pedia t r 
Gas t roentero l Nu t r 1992; 14: 3 -11 . 
27. Zhou X, Li Y X , Li N , Li JS. G lu tamine enhances the 
gut- t rophic e f fec t o f g rowth h o r m o n e in rat a f te r 
mass ive small bowel resect ion. J Surg Res 2 0 0 1 ; 99: 
47-52 . 
28. Ladd AP, Gros fe ld JL, Pescov i t z O H , Johnson N B . T h e 
e f fec t of g rowth h o r m o n e supplementa t ion on late 
nutri t ional i ndependence in pediat r ic pat ients with short 
bowel syndrome. J Pedia t r Surg 2 0 0 5 ; 40: 4 4 2 - 4 4 5 . 
29. Nucc i A M , Finegold D N , Yaworsk i JA, Kowalsk i L, 
Barksda le E M Jr. Resul t s o f g rowth t rophic therapy in 
chi ldren with short bowel syndrome . J Pedia t r Surg 
2004 ; 39: 335 -339 ; d iscuss ion 335-339 . 
30. Moy le GJ, Daar ES, Ger tne r JM, Kot ler DP, Melch io r 
JC, O ' B r i e n F, S v a n b e r g E; Se rono 9037 Study T e a m . 
Growth h o r m o n e improves lean body mass , physical 
pe r fo rmance , and qual i ty o f life in subjec ts with H I V -
associa ted weight loss or was t ing on highly act ive 
ant iretroviral therapy. J Acqui r Immune Def ic Syndr 
2 0 0 4 ; 35: 367 -375 . 
31. Wal lace JD, Abbo t t - Johnson WJ , C r a w f o r d D H , 
Barnard R, Pot ter J M , C u n e o RC. G H t rea tment in 
adul ts with chronic liver d isease: a r andomized , doub le -
blind, p lacebo-con t ro l l ed , c ross -over study. J Clin 
Endocr inol M e t a b 2 0 0 2 ; 87: 275 I -2759 . 
V O L U M E 2 I . N O . 8. 2008 

